# Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations

> **NCT05293626** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Neurophth Therapeutics Inc** · enrollment: 12 (actual)

## Conditions studied

- Leber Hereditary Optic Neuropathy (LHON)

## Interventions

- **DRUG:** NR082 Injection
- **DEVICE:** Injection needle

## Key facts

- **NCT ID:** NCT05293626
- **Lead sponsor:** Neurophth Therapeutics Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-22
- **Primary completion:** 2025-07
- **Final completion:** 2029-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05293626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05293626, "Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05293626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*